【摘要】：正Protalix生物治療藥公司宣布,在小鼠法布雷病模型上pegunigalsidase alfa,與市售酶替代治療藥及未給予治療的小鼠比較,證實可延緩小纖維神經(jīng)病發(fā)展。此次臨床前研究中,該藥1 mg/kg、市售藥β阿加糖苷酶(Fabrazyme)和α阿加糖苷酶(Replagal)分別為1和0.2 mg/kg,給法布雷病小鼠每2周1次靜脈滴注,與不給藥法布雷病小鼠和野生型健康小鼠進行比較,共3個月。用α半乳糖苷酶治療的法布雷病小鼠,與不給藥法
[Abstract]:Protalix Biotherapeutic Drug Company announced that pegunigalsidase alfa, could delay the development of microfibrillary neuropathy in mice with Fabr's disease model compared with those sold on the market and without treatment. In this preclinical study, 尾 -agar glucosidase (Fabrazyme) and 偽 -agar glucosidase (Replagal) were 1 and 0. 2 mg/kg, respectively by intravenous drip once every 2 weeks in mice with Fabr's disease. The results were compared with the control mice and the wild type healthy mice for 3 months. Fabr disease mice treated with 偽 galactosidase
【分類號】：R971

【相似文獻】

相關期刊論文 前1條

1 劉安珍,趙保生,于子風,王家彬;氨基糖甙類抗生素不同給藥法療效比較[J];臨床薈萃;1997年18期

，

本文編號：2265747